Novagali Pharma Releases Data Pertaining to BAK-Free Eye Drops for Glaucoma Treatment

February 27, 2009

Novagali Pharma, a French pharmaceutical ophthalmic company, announced the results of its first set of data pertaining to Nova21027, a BAK-free latanoprost formulation for glaucoma. The data was presented at the 9th Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) held in Salzburg, Austria.

According to Novagali’s press release, acute toxicological studies confirm the ocular surface toxicity of anti-glaucomatous eye drops containing benzalkonimum chloride (BAK). In contrast, Novagali’s BAK-free cationic emulsion of latanoprost was well tolerated and did not induce any ocular surface damages upon stress conditions.

The company noted that the safer profile is of paramount importance taking into account that BAK exerts toxicity after long term use and that glaucoma is a chronic disease needing life-long daily treatment.

Read the full release on the IT News website.




Jump down to form below to submit your own comments

Comments are closed.